Oruka Therapeutics Inc ORKA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-07-21 |
| Shares Out. | 60,310,000 |
| Website | orukatx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 68 |
| Net Income | -$31.8M |
| Free Cash Flow | -$91.2M |
| Total Assets | $504.5M |
| Total Liabilities | $17.8M |
| Equity | $486.7M |
About Oruka Therapeutics Inc
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Oruka Therapeutics Inc is a publicly traded company under the ticker symbol ORKA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)